Exercise Capacity in Polycystic Kidney Disease

Background Reports about exercise performance in autosomal dominant polycystic kidney disease (ADPKD) are scarce. We aimed to evaluate exercise capacity and levels of nitric oxide and asymmetric dimethylarginine (ADMA) in normotensive patients with ADPKD. Study Design Prospective controlled cohort s...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of kidney diseases Vol. 64; no. 2; pp. 239 - 246
Main Authors Reinecke, Natália Lopes, MSc, Cunha, Thulio Marquez, MD, PhD, Heilberg, Ita Pfeferman, MD, PhD, Higa, Elisa Mieko Suemitsu, MD, PhD, Nishiura, José Luiz, MD, PhD, Neder, José Alberto, MD, PhD, Almeida, Waldemar Silva, MD, PhD, Schor, Nestor, MD, PhD
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.08.2014
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Reports about exercise performance in autosomal dominant polycystic kidney disease (ADPKD) are scarce. We aimed to evaluate exercise capacity and levels of nitric oxide and asymmetric dimethylarginine (ADMA) in normotensive patients with ADPKD. Study Design Prospective controlled cohort study. Setting & Participants 26 patients with ADPKD and 30 non-ADPKD control participants (estimated glomerular filtration rate > 60 mL/min/1.73 m2 , aged 19-39 years, and blood pressure [BP] < 140/85 mm Hg). We excluded smokers, obese people, and individuals with associated diseases. Predictor ADPKD versus control. Outcomes Exercise capacity and nitric oxide and ADMA levels in response to exercise. Measurements Cardiopulmonary exercise testing and serum and urinary nitric oxide, plasma ADMA, and BP levels before and after exercise. Results Mean basal systolic and diastolic BP, estimated glomerular filtration rate, and age did not differ between the ADPKD and control groups (116 ± 12 vs 110 ± 11 mm Hg, 76 ± 11 vs 71 ± 9 mm Hg, 113 ± 17 vs 112 ± 9.6 mL/min/1.73 m2 , and 30 ± 8 vs 28.9 ± 7.3 years, respectively). Peak oxygen uptake and anaerobic threshold were significantly lower in the ADPKD group than in controls (22.2 ± 3.3 vs 31 ± 4.8 mL/kg/min [ P < 0.001] and 743.6 ± 221 vs 957.4 ± 301 L/min [ P = 0.01], respectively). Postexercise serum and urinary nitric oxide levels in patients with ADPKD were not significantly different from baseline (45 ± 5.1 vs 48.3 ± 4.6 μmol/L and 34.7 ± 6.5 vs 39.8 ± 6.8 μmol/mg of creatinine, respectively), contrasting with increased postexercise values in controls (63.1 ± 1.9 vs 53.9 ± 3.1 μmol/L [ P = 0.01] and 61.4 ± 10.6 vs 38.7 ± 5.6 μmol/mg of creatinine [ P = 0.01], respectively). Similarly, whereas postexercise ADMA level did not change in the ADPKD group compared to those at rest (0.47 ± 0.04 vs 0.45 ± 0.02 μmol/L [ P = 0.6]), it decreased in controls (0.39 ± 0.02 vs 0.47 ± 0.02 μmol/L [ P = 0.006]), as expected. A negative correlation between nitric oxide and ADMA levels after exercise was found in only the control group ( r = −0.60; P < 0.01). Limitations Absence of measurements of flow-mediated dilatation and oxidative status. Conclusions We found lower aerobic capacity in young normotensive patients with ADPKD with preserved kidney function and inadequate responses of nitric oxide and ADMA levels to acute exercise, suggesting the presence of early endothelial dysfunction in this disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0272-6386
1523-6838
DOI:10.1053/j.ajkd.2014.03.014